JPRN-UMIN000008366已完成2 期
A phase II study of gefitinib with concurrent thoracic radiotherapy in patients with unresectable, stage III Non-Small Cell Lung Cancer harboring EGFR mutations. - A phase II study of gefitinib with TRT in patients with stage III NSCLC harboring EGFR mutations.
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 28
研究概览
简要总结
Among unresectable locally-advanced NSCLC patients with EGFR mutation, gefitinib with concurrent thoracic radiotherapy showed manageable safety profiles, but did not improve PFS rate at 2 years.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Harboring exon 20 T790M mutation. 2) Incapable of oral intake 3) With intestinal paralysis, or ileus 4) Chronic diarrhea 5)Exhibiting significant interstitial pneumonitis, or pulmonary fibrosis in the chest CT 6) Active infection 7) Positive for HBs antigen 8) Uncontrolled diabetes mellitus 9) Severe heart disease 10) Systemic treatment with steroids 11) Concomitant cancers within 5 years 12) Prior history of thoracic radiotherapy 13) History of sereous drug allegies 14) Pregnancy, breast feeding, or hesitation in contraception 15) Other conditions not suitable for this study
研究者
相似试验
已完成
2 期
A phase II study of gefitinib with TRT in patients with stage III NSCLC harboring EGFR mutationson-Small Cell Lung CancerJPRN-jRCTs041180080Murakami Haruyasu28
Unknown
2 期
EGFR Mutation Positive NSCLC Patients With Gefitinib and ThalidomideNSCLC Stage IVChemotherapy EffectNCT03341494Fujian Cancer Hospital128
终止
2 期
Iressa Re-challenge in Advanced NSCLC EGFR-mutated PatientsLung CancerNCT02025218Amsterdam UMC, location VUmc21
Unknown
2 期
Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With GefitinibEGFR Gene MutationNon-small Cell Lung CancerNCT04358562Second Affiliated Hospital of Nanchang University240
已完成
2 期
Phase II study of gefitinib in patients with EGFR mutation positive- advanced non-small cell lung cancernon-small cell lung cancerJPRN-C000000151West Japan Oncology Group25